亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

原料奧氮平

 
 
單價(jià) 1.00 / 千克對(duì)比
銷量 暫無
發(fā)貨 湖北武漢市付款后24小時(shí)內(nèi)
庫(kù)存 1000千克起訂25千克
品牌 潤(rùn)德
CAS 132539-06-1
名稱 奧氮平
包裝 1*25千克
過期 長(zhǎng)期有效
更新 2016-06-13 14:48
 

湖北鑫潤(rùn)德化工有限責(zé)任公司

企業(yè)會(huì)員第12年
資料未認(rèn)證
保證金未繳納
  • 湖北-武漢市
  • 上次登錄 2016-06-13
  • 廖興國(guó) (先生)   經(jīng)理
詳細(xì)說明
 奧氮平
 
奧氮平別名:2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩并[2,3-b][1,5]苯并二氮雜 
奧氮平英文名:Olanzapine   
奧氮平分子式:C17H20N4S   
奧氮平分子量:312.43   
奧氮平CAS號(hào):132539-06-1   
奧氮平性狀:淡黃色或黃色結(jié)晶性粉末
奧氮平質(zhì)量標(biāo)準(zhǔn):99%
奧氮平小包裝:1公斤鋁箔袋或其他
奧氮平用途:奧氮平適用于精神分裂癥和其它有嚴(yán)重陽(yáng)性癥狀(例如:妄想、幻覺、思維障礙、敵意和猜疑)和/或陰性癥狀(例如:情感淡漠、情感和社會(huì)退縮、言語(yǔ)貧乏)的精神病的急性期和維持治療。奧氮平亦可緩解精神分裂癥及相關(guān)疾病常見的繼發(fā)性情感癥狀。對(duì)于取得初步療效、需要繼續(xù)治療。
奧氮平包裝:紙板桶25KG/桶
我公司主要生產(chǎn):氨基比林,保泰松,吡羅昔康,非那西丁,撲熱息痛
舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |